



illumiSonics Announces the Appointment of Steve Basta as Chairman of the Board

November 8, 2023 - illumiSonics Inc., (“company”) a leading company in optical imaging systems providing unprecedented cellular and molecular data, is pleased to announce that Mr. Steven Basta has been appointed as chairman of the board of directors effective October 20, 2023. Mr. Basta succeeds Dr. Parsin Haji Reza, who had formerly served as the company’s chairman and who will continue to serve as founder, chief technology officer and director.

“As the company transitions into the development and commercialization of its first products, it is with great enthusiasm that we welcome Steve to our team. Steve’s life science expertise, corporate governance experience, and support of our vision will be invaluable at this pivotal juncture. I eagerly look forward to the contributions he will bring to our company,” said Parsin Haji Reza.

Mr. Basta is a seasoned healthcare executive with broad experience leading biopharma and medical technology companies. Over the past 25 years, Mr. Basta has led multiple life science companies in developing and commercializing biopharma and medical device technologies. Steve has successfully led two companies through initial public offerings and has led multiple partnerships, private financings, mergers, and licensing collaborations. Steve served as chief executive officer of BioForm Medical through product development, initial commercial launch and scale-up of a leading injectable aesthetics business, making it a worldwide leader in the dermal filler space, and ultimately a leader broadly in medical aesthetics. Mr. Basta currently serves as chief executive officer of Sanotize, a Vancouver-based pharmaceutical and medical device company, and as a board director of VYNE Therapeutics and Dermibiont.

Mr. Basta commented, “I’m delighted to be joining illumiSonics Inc., at a key inflection point for the company. IllumiSonics has demonstrated that PARS can sense more about the composition of tissue than has ever been measured previously in an imaging system. We are positioned to bring the science into commercial application to transform clinical pathology laboratories and to create new applications made possible for the first time through this technology. I’m pleased to be a part of the team to help realize the potential of this imaging breakthrough.”

“On behalf of the entire board, we would like to thank Parsin for his continuing contributions to the company and for his historical leadership as former chairman of the board. We are very excited to have Steve join our team and for the contributions he will undoubtedly make as we seek to dramatically change the medical imaging space,” said Scott Durbin, chief executive officer.

About illumiSonics Inc.

illumiSonics Inc. is a Waterloo, Ontario company that has developed the PARS[®] (photon absorption remote sensing) optical imaging platform, a revolutionary non-contact, high-resolution, label-free, non-destructive imaging modality. PARS[®] captures all light-matter interactions to give unprecedented deep data, which can then be processed using AI to yield multiple virtual histopathology images. PARS can generate multiple diagnoses from a single tissue sample which has the potential to dramatically change the imaging of both fixed and fresh tissue samples. For more information, visit www.illumisonics.com.